Universal Pneumococcus Antigen Simulator

Scientific Scenario Presets

🔬 Bacterial Envelope & Conserved Antigen Binding Kinetic Stage

Challenge Strain: Serotype 19A (Capsule: 45nm)

Drag mouse / tap inside to inject target antibodies & test capsule penetration

Bound Ab: 0 | Complement C3b: Active | Phagocytosis: Ready

PspA Stalk (Conserved)

PcpA Surface Adhesin

PhtD Histidine Triad

Polysaccharide Capsule Barrier

Engulfing Macrophage

Broad Neutralization High (96/100 isolates) Universal Tier

Universal Cocktail Coverage 96.0% Serotype Independent

PCV20 Capsular Coverage 58.0% 42 Non-Vaccine Gaps

Replacement Escape Risk Minimal (<4%) Conserved Anchor

🧫 100 Clinical S. pneumoniae Isolates Clearance Matrix

Cleared: 96 / 100

Isolates 001 - 100 (Color represents strain neutralization & clearance status under current formulation)

Complete Clearance (OPK >85%)

Partial Neutralization

Capsule Escape / Uncovered

⚙️ Vaccine Antigen Formulation

Vaccine Platform Class

Active Conserved Antigen Targets

PspA (Pneumococcal Surface Protein A - Clades 1-5) PcpA (Pneumococcal Choline-binding Protein A) PhtD (Pneumococcal Histidine Triad Protein D)

Serum Antibody Titre (μg/mL) 24.0 μg/mL

Capsule Thickness Resistance (nm) 45 nm

📈 Opsonophagocytic Killing (OPK) Assay

91.0% Killing

T=0m (Complement C3b Opsonization) T=60m (Macrophage Lysis)

📋 Molecular Mechanism & Escapes

[Mechanism Overview] • S. pneumoniae possesses >100 distinct polysaccharide capsule serotypes. • PCV13 & PCV20 induce serotype replacement: unvaccine strains (e.g. 35B, 23B) expand into vacant nasopharyngeal niches. • Conserved protein targets (PspA, PcpA, PhtD) extend through the capsule matrix, allowing broadly neutralizing IgG deposition and C3b-mediated opsonophagocytosis across virtually all serotypes.